Inari Medical, a company that develops devices for venous and other diseases, has agreed to buy LimFlow, a company that offers a minimally-invasive solution for patients with severe peripheral artery disease who face leg amputation.
The deal is worth up to $415 million and is expected to close by the end of 2023. LimFlow’s technology, which received FDA approval in September 2023, restores blood flow in deep veins and has shown promising results in clinical trials.
LimFlow’s CEO, Dan Rose, said that the acquisition will increase patient access and address crucial unmet needs in vascular disease. Inari’s CEO, Drew Hykes, said that the acquisition will add another growth platform to Inari’s portfolio and that he sees the CLTI market as poised for durable growth.
Leave a Reply